Global Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

Global Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

Global scleroderma therapeutics market is expected to grow at a CAGR of 5.2% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.
Market Segmentation
By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026
Major growing sectors under the market segmentation are as follows:

• In type, systemic scleroderma segment is dominating due to its awareness and treatment availability for its associated diseases. There are many products for this segment on which the clinical trials are going on.

• In treatment type, the drug treatment is growing segment as there are various drugs available in the market for the treatment of scleroderma related complications.

• In end user, hospital has a larger market than other end users because the treatment takes place majorly in hospitals.

Key Market Players

The key market players for global scleroderma therapeutics market are listed below:

• Argentis Pharmaceuticals, LLC.
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• Pfizer Inc.
• Sanofi
• ALLERGAN
• viDA Therapeutics Inc.
• Novartis AG
• Active Biotech AB.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Johnson & Johnson Services, Inc.
• AstraZeneca
• Daval International Limited
• Others

The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of Global Scleroderma Therapeutics Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Global Scleroderma Therapeutics Market : Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Dbmr Tripod Data Validation Model
2.6 Primary Interviews With Key Opinion Leaders
2.7 Dbmr Market Position Grid
2.8 Time Line
2.9 Multivariate Modelling
2.10 Secondary Sources
2.11 Assumptions
3 Market Overview
3.1 Drivers
3.1.1 Rising Cases Of Scleroderma
3.1.2 Increasing Access To Medical Insurance In The U.S.
3.1.3 Increasing Merger And Acquisitions
3.2 Restraints
3.2.1 Lack Of Curative Treatment
3.2.2 Stringent Regulations
3.2.3 Counterfeit Products
3.3 Opportunity
3.3.1 Unmet Patient Needs In Systemic Sclerosis
3.4 Challenge
3.4.1 Side Effects Of Drugs
4 Executive Summary
5 Premium Insights
6 Pipeline Products
7 Epidemiology
7.1 History Of Scleroderma:
7.2 Recent Incidence And Prevalence:
7.3 Cause Of Scleroderma:
7.4 Symptoms Of Scleroderma:
7.5 Managing Scleroderma:
8 Global Scleroderma Therapeutics Market, By Type
8.1 Overview
8.2 Systemic Scleroderma
8.2.1 Limited Cutaneous Systemic Sclerosis Or Crest Syndrome
8.2.2 Diffuse Systemic Sclerosis
8.3 Localized Scleroderma
8.3.1 Morphea
8.3.2 Linear Scleroderma
9 Global Scleroderma Therapeutics Market, By Treatment Type
9.1 Overview
9.2 Drug Treatment
9.2.1 Drug Treatment, By Type
9.2.1.1 Anti-inflammatory Drugs
9.2.1.2 Immunosuppressants
9.2.1.3 Corticosteroids
9.2.1.4 Proton Pump Inhibitors
9.2.1.5 Calcium Channel Blockers
9.2.1.6 Ace Inhibitors
9.2.1.7 H2 Blockers
9.2.1.8 Pde5 Inhibitors
9.2.1.9 Prostacyclin Analogues
9.2.1.10 Endothelin Receptor Antagonists
9.2.1.11 Chelating Agents (Edathamil Disodium)
9.2.1.12 Others
9.2.2 Drug Treatment, By Distribution Channel
9.2.2.1 Hospital Pharmacy
9.2.2.2 Retail Pharmacy
9.2.2.3 Online Pharmacy
9.2.2.4 Others
9.3 Surgical Treatment
9.4 Therapy
9.4.1 Ultraviolet Light Therapy
9.4.2 Physical Therapy
9.4.3 Others
10 Global Scleroderma Therapeutics Market, By End User
10.1 Overview
10.2 Hospital
10.3 Specialty Clinics
10.4 Homecare Settings
10.5 Others
11 Global Scleroderma Therapeutics Market, By Geography
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K.
11.3.2 Germany
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Netherlands
11.3.7 Switzerland
11.3.8 Belgium
11.3.9 Turkey
11.3.10 Russia
11.3.11 Rest Of Europe
11.4 Asia-pacific
11.4.1 Japan
11.4.2 China
11.4.3 Australia
11.4.4 South Korea
11.4.5 India
11.4.6 Singapore
11.4.7 Malaysia
11.4.8 Indonesia
11.4.9 Thailand
11.4.10 Philippines
11.4.11 Rest Of Asia-pacific
11.5 South America
11.5.1 Brazil
11.5.2 Rest Of South America
11.6 Middle East & Africa
11.6.1 South Africa
11.6.2 Rest Of Middle East & Africa
12 Global Scleroderma Therapeutics Market, Company Landscape
12.1 Company Share Analysis: Global
13 Company Profiles
13.1 Astrazeneca
13.1.1 Company Snapshot
13.1.2 Revenue Analysis
13.1.3 Geographical Presence
13.1.4 Product Portfolio (Pipeline)
13.1.5 Recent Developments
13.2 F. Hoffmann-la Roche Ltd
13.2.1 Company Snapshot
13.2.2 Reveneue Analysis
13.2.3 Geographical Presence
13.2.4 Product Portfolio
13.2.5 Recent Developments
13.3 Novartis Ag
13.3.1 Company Snapshot
13.3.2 Reveneue Analysis
13.3.3 Geographical Presence
13.3.4 Product Portfolio
13.3.5 Recent Developments
13.4 Pfizer Inc.
13.4.1 Company Snapshot
13.4.2 Reveneue Analysis
13.4.3 Geographical Presence
13.4.4 Product Portfolio
13.4.5 Recent Developments
13.5 Abbvie Inc.
13.5.1 Company Snapshot
13.5.2 Reveneue Analysis
13.5.3 Geographical Presence
13.5.4 Product Portfolio
13.5.5 Recent Developments
13.6 Active Biotech Ab.
13.6.1 Company Overview
13.6.2 Revenue Analysis
13.6.3 Product Portfolio
13.6.4 Recent Development
13.7 Allergan
13.7.1 Company Snapshot
13.7.2 Reveneue Analysis
13.7.3 Geographical Presence
13.7.4 Product Portfolio
13.7.5 Recent Developments
13.8 Argentis Pharmaceuticals, Llc.
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Recent Developments
13.9 Bristol-myers Squibb Company
13.9.1 Company Overview
13.9.2 Revenue Analysis
13.9.3 Geographical Presence
13.9.4 Products Portfolio
13.9.5 Recent Developments
13.10 Daval International Limited
13.10.1 Company Snapshot
13.10.2 Geographical Presence
13.10.3 Product Portfolio
13.10.4 Recent Development
13.11 Glaxosmithkline Plc.
13.11.1 Company Overview
13.11.2 Revenue Analysis
13.11.3 Geographical Presence
13.11.4 Products Portfolio (Pipeline Development)
13.11.5 Recent Development
13.12 Johnson & Johnson Services, Inc.
13.12.1 Company Overview
13.12.2 Revenue Analysis
13.12.3 Geographical Presence
13.12.4 Product Portfolio (Pipeline)
13.12.5 Recent Developments
13.13 Sanofi
13.13.1 Company Snapshot
13.13.2 Reveneue Analysis
13.13.3 Geographical Presence
13.13.4 Product Portfolio
13.13.5 Recent Development
13.14 Vida Therapeutics Inc.
13.14.1 Company Overview
13.14.2 Product Portfolio
13.14.3 Recent Developments
14 Questionnaire
15 Related Reports
List Of Figures
Figure 1 Below Is The Scleroderma Map Defining The Types
Figure 2 Global Scleroderma Therapeutics Market: Segmentation
Figure 3 Global Scleroderma Therapeutics Market: Data Triangulation
Figure 4 Global Scleroderma Therapeutics Market: Droc Analysis
Figure 5 Global Scleroderma Therapeutics Market: Global Vs Regional Market Analysis
Figure 6 Global Scleroderma Therapeutics Market: Company Research Analysis
Figure 7 Global Scleroderma Therapeutics Market: Interview Demographics
Figure 8 Global Scleroderma Therapeutics Market: Dbmr Market Position Grid
Figure 9 Drivers, Restraints, Opportunities And Challenges Of Global Scleroderma Therapeutics Market
Figure 10 Global Scleroderma Therapeutics Market: Segmentation
Figure 11 North America Is Anticipated To Dominate The Global Scleroderma Therapeutics Market And Estimated To Be Increasing With The Highest Cagr In The Forecast Period From 2019 To 2026
Figure 12 Rising Cases Of Scleroderma, Increasing Access To Medical Insurance In The U.S., Increasing Merger And Acquisitions Is Expected To Drive The Global Scleroderma Therapeutics Market In The Forecast Period 2019 To 2026
Figure 13 Systemic Scleroderma Is Expected To Account For The Largest Share Of The Global Scleroderma Therapeutics Market In 2019 & 2026
Figure 14 North America Is The Maximum Growing And Most Profitable Revenue Pockets For Global Scleroderma Therapeutics Market In The Forecast Period From 2019 To 2026
Figure 15 Global Scleroderma Therapeutics Market: By Type , 2018
Figure 16 Global Scleroderma Therapeutics Market: By Treatment Type , 2018
Figure 17 Global Scleroderma Therapeutics Market: By End User, 2018
Figure 18 Global Scleroderma Therapeutics Market: Snapshot (2018)
Figure 19 Global Scleroderma Therapeutics Market: By Geography (2018)
Figure 20 Global Scleroderma Therapeutics Market: By Geography (2019 & 2026)
Figure 21 Global Scleroderma Therapeutics Market: By Geography (2018 & 2026)
Figure 22 Global Scleroderma Therapeutics Market: By Type (2019-2026)
Figure 23 North America Scleroderma Therapeutics Market: Snapshot (2018)
Figure 24 North America Scleroderma Therapeutics Market: By Country (2018)
Figure 25 North America Scleroderma Therapeutics Market: By Country (2019 & 2026)
Figure 26 North America Scleroderma Therapeutics Market: By Country (2018 & 2026)
Figure 27 North America Scleroderma Therapeutics Market: By Type (2019-2026)
Figure 28 Europe Scleroderma Therapeutics Market: Snapshot (2018)
Figure 29 Europe Scleroderma Therapeutics Market: By Country (2018)
Figure 30 Europe Scleroderma Therapeutics Market: By Country (2019 & 2026)
Figure 31 Europe Scleroderma Therapeutics Market: By Country (2018 & 2026)
Figure 32 Europe Scleroderma Therapeutics Market: By Type (2019-2026)
Figure 33 Asia-pacific Scleroderma Therapeutics Market: Snapshot (2018)
Figure 34 Asia-pacific Scleroderma Therapeutics Market: By Country (2018)
Figure 35 Asia-pacific Scleroderma Therapeutics Market: By Country (2019 & 2026)
Figure 36 Asia-pacific Scleroderma Therapeutics Market: By Country (2018 & 2026)
Figure 37 Asia-pacific Scleroderma Therapeutics Market: By Type (2019-2026)
Figure 38 South America Scleroderma Therapeutics Market: Snapshot (2018)
Figure 39 South America Scleroderma Therapeutics Market: By Country (2018)
Figure 40 South America Scleroderma Therapeutics Market: By Country (2019 & 2026)
Figure 41 South America Scleroderma Therapeutics Market: By Country (2018 & 2026)
Figure 42 South America Scleroderma Therapeutics Market: By Type (2019-2026)
Figure 43 Middle East & Africa Scleroderma Therapeutics Market: Snapshot (2018)
Figure 44 Middle East & Africa Scleroderma Therapeutics Market: By Country (2018)
Figure 45 Middle East & Africa Scleroderma Therapeutics Market: By Country (2019 & 2026)
Figure 46 Middle East & Africa Scleroderma Therapeutics Market: By Country (2018 & 2026)
Figure 47 Middle East & Africa Scleroderma Therapeutics Market: By Type (2019-2026)
Figure 48 Global Scleroderma Therapeutics Market: Company Share 2018 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook